Palabras clave
Odontología preventiva
Fármacos antirresortivos
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Verificar el nivel de derivación de pacientes en tratamiento con fármacos antirresortivos, en cuanto al seguimiento odontológico, con el objetivo de prevenir la osteonecrosis de la mandíbula. Métodos: Este estudio se llevó a cabo en el Ambulatorio de Reumatología del Hospital Universitario Lauro Wanderley e incluyó a 71 pacientes que utilizaban fármacos antirresortivos. Se realizó una entrevista estructurada, mediante un cuestionario con preguntas de opción múltiple. El material recolectado fue analizado con base en el método cuantitativo. El ingreso de datos se realizó en la plataforma Google Forms para obtener valores porcentuales. Resultados: La mayoría de los pacientes (77,5%) no fueron informados sobre los efectos secundarios del medicamento. Respecto a la derivación que realiza el médico al dentista antes de iniciar el tratamiento con estos fármacos, sólo el 7% de los pacientes fueron derivados. Un porcentaje del 70,8% de los pacientes acudió al dentista sólo cuando necesitaba tratamiento. Conclusión: El estudio destaca la baja tasa de derivación al dentista de pacientes que utilizan terapia antirresortiva, asociada a la alta prevalencia de pacientes que buscan al dentista sólo cuando necesitan algún tratamiento.
Referencias
CAMPISI G, et al. Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. International Journal of Environmental Research and Public Health, 2020; 17(16).
DE CARVALHO EF, et al. Cilostazol and Tocopherol in the Management of Medication-Related Osteonecrosis of the Jaw: New Insights From a Case Report. Journal of Oral and Maxillofacial Surgery, 2021; 79(12): 2499-2506.
DE-FREITAS NR, et al. Bisphosphonate treatment and dental implants: A systematic review. Medicina oral, patologia oral y cirurgia bucal, 2016; 21(5): 644-651.
DOS SANTOS WB, et al. Osteonecrose dos Maxilares associada ao uso crônico de bisfosfonatos: relato de caso. Revista Eletrônica Acervo Saúde, 2020; 12(2): 2398-2398.
EASTELL R, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 2019; 104(5): 1595-1622.
FEDELE S, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. British Journal of Oral and Maxillofacial Surgery, 2015; 53(1): 13-17.
GAUDIN E, et al. Occurrence and risk indicators of medication‐related osteonecrosis of the jaw after dental extraction: a systematic review and meta‐ analysis. Journal of Clinical Periodontology, 2015; 42(10): 922-932.
HAYASHIDA S, et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. Journal of Bone and Mineral Metabolism, 2020; 38: 126-134.
HEIFETZ-LI JJ, et al. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology and oral radiology, 2019; 128(5): 491-4972.
KARNA H, et al. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses. Oral Oncology, 2018; 85: 15-23.
KEMP APT, et al. Fatores de risco para osteonecrose dos maxilares relacionada à medicação e níveis salivares de IL-6 em pacientes com câncer. Brazilian Journal of Otorhinolaryngology, 2022; 88(5): 683-690.
KHAN A A, et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. Journal of clinical densitometry, 2017; 20(1): 8-24.
LORENZO-POUSO AI, et al. Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review. Medicina oral, patologia oral y cirugia bucal, 2019; 24(1): 26-36.
MADEIRA M, et al. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis–A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso). Archives of endocrinology and metabolism, 2020; 64(6): 664- 672.
MCGOWAN K, et al. Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study. Clinical Oral Investigations, 2019; 23: 3967-3975.
MCGOWAN K, et al. Systemic comorbidities are associated with medication‐related osteonecrosis of the jaws: Case–control study. Oral Diseases, 2019; 25(4): 1107-1115.
NGUYEN AP e SMITH L. Medication-related osteonecrosis of the jaw (MRONJ). Adawa clinical resource, 2022.
NICOLATOU‐GALITIS O, et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone‐targeting agents. Oral Diseases, 2020; 26(5): 955-966.
NICOLATOU-GALITIS O, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral surgery, oral medicine, oral pathology and oral radiology, 2019; 127(2): 117-135.
POLI PP, et al. Adjunctive application of antimicrobial photodynamic therapy in the prevention of medication-related osteonecrosis of the jaw following dentoalveolar surgery: A case series. Photodiagnosis and photodynamic therapy, 2019; 27: 117-123.
RAMAGLIA L, et al. Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clinical oral investigations, 2018; 22: 597-615.
RUGGIERO S, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of oncology practice, 2006; 2(1): 7-14.
RUGGIERO SL, et al. American Association of Oral and Maxillofacial Surgeons’ Position Paper on medication-related osteonecrosis of the jaw–2022 update. Journal of oral and maxillofacial surgery, 2022; 80(5): 920-943.
SOARES AL, et al. Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: a cross-sectional study. Supportive Care in Cancer, 2020; 28: 2265-2271.
VELASKI DP, et al. Etiopatogenia da osteonecrose maxilar relacionada a bisfosfonatos. Biosaúde, 2020; 22(2): 84-96.
WAN JT, et al. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone research, 2020; 8(14).